All In Biotech

NDA 021011 · Specgx LLC

Roxicodone

Oxycodone Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Aug 31, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

646

137 Phase 3, 50 recruiting

FAERS reports

92,014

81,137 serious, 32,198 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF ROXICODONE Addiction, Abuse, and Misuse Because the use of ROXICODONE exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of ROXICODONE, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of ROXICODONE are essential [see Warnings and Precautions ( 5.2 )] . Accidental Ingestion Accidental ingestion of even one dose of ROXICODONE, especially by children, can result in a fatal overdose of...

What it is approved for

From the label in effect Apr 24, 2026.

ROXICODONE is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions ( 5.1 )] , reserve opioid analgesics, including ROXICODONE for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ROXICODONE is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use: Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including ROXICODONE for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 )

Mechanism: Oxycodone is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ROXICODONE · OXYCODONE HYDROCHLORIDE 30MG · TABLET, ORAL · Prescription · TE AB
  • ROXICODONE · OXYCODONE HYDROCHLORIDE 5MG · TABLET, ORAL · Prescription · TE AB
  • ROXICODONE · OXYCODONE HYDROCHLORIDE 15MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxycodone" as an intervention, any sponsor and status, largest first.

All 646 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence27,118
  • pain19,074
  • overdose17,568
  • emotional distress15,366
  • death14,251
  • toxicity to various agents12,632
  • drug withdrawal syndrome10,112
  • fatigue4,126
  • drug ineffective4,075
  • drug abuse3,739
  • nausea3,739
  • anxiety2,931

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200446
200560
2006104
2007108
2008181
2009160
2010263
2011272
2012603
2013865
2014771
20151,070
20162,492
20174,304
201825,281
20193,325
20205,469
202114,161
202215,910
20234,654
20244,197
20254,453
20263,265

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Roxicodone (Oxycodone HCl)

2024 spending

$1.6M

Beneficiaries

177

1,525 claims

Per beneficiary

$9,242

$7.95 per unit

View as table
YearSpending
2020$2,962,224
2021$2,508,018
2022$1,982,538
2023$1,952,761
2024$1,635,815

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,201 on PubMed

Sponsor: Specgx LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.